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Abstract
Background: Breast cancer is the most common malignant disease amongst Western women. The lack of
treatment options for patients with chemotherapy-resistant or recurrent cancers is pushing the field toward the
rapid development of novel therapies. The use of oncolytic viruses is a promising approach for the treatment of
disseminated diseases like breast cancer, with the first candidate recently approved by the Food and Drug
Administration for use in patients. In this report, we demonstrate the compatibility of oncolytic virotherapy and
chemotherapy using various murine breast cancer models. This one-two punch has been explored in the past by
several groups with different viruses and drugs and was shown to be a successful approach. Our strategy is to
combine Paclitaxel, one of the most common drugs used to treat patients with breast cancer, and the oncolytic
Rhabdovirus Maraba-MG1, a clinical trial candidate in a study currently recruiting patients with late-stage
metastatic cancer.
Methods: We used the EMT6, 4 T1 and E0771 murine breast cancer models to evaluate in vitro and in vivo the effects
of co-treatment with MG1 and Paclitaxel. Treatment-induced cytotoxicity was assessed and plaque assays, flow
cytometry, microscopy and immunocytochemistry analysis were performed to quantify virus production and transgene
expression. Orthotopically implanted tumors were measured during and after treatment to evaluate efficacy and
Kaplan-Meier survival curves were generated.
Results: Our data demonstrate not only the compatibility of the treatments, but also their synergistic cytopathic
activity. With Paclitaxel, EMT6 and 4 T1 tumors demonstrated increased virus production both in vitro and in vivo. Our
results also show that Paclitaxel does not impair the safety profile of the virus treatment. Importantly, when combined,
MG1 and the drug controlled tumor growth and prolonged survival.
Conclusions: The combination of MG1 and Paclitaxel improved efficacy in all of the breast cancer models we tested
and thus is a promising alternative approach for the treatment of patients with refractory breast cancer. Our strategy
has potential for rapid translation to the clinic, given the current clinical status of both agents.
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Background
Breast cancer is a highly aggressive disease with most of
the deaths resulting from metastases within the first
three years upon diagnosis [1]. Metastatic human triple-
negative breast cancer (TNBC) has the worst prognosis
among all types of breast cancer, with high risk of rapid
recurrence and shortened survival [2]. TNBC is deficient
in the expression of estrogen receptor, progesterone recep-
tor and human epidermal growth factor receptor 2, and
thus, is refractory to conventional breast cancer hormonal
therapy such as Tamoxifen. The main therapeutic option
with surgery is chemotherapy, but some subsets of tumor
are resistant and the prognosis for these patients is poor
[3]. The standard of care for TNBC is the administration
of anthracyclines and/or taxanes [2]. Paclitaxel (PAC),
also called Taxol, is a cancer chemotherapeutic agent of
the taxane family that acts by stabilizing microtubules
and thus preventing cell division [4]. PAC is commonly
used as monotherapy or in combination with different
agents. Significant effort is currently being directed to-
ward improving its efficacy and developing alternate
strategies for the treatment of chemotherapy-resistant
and recurrent disease.
A novel strategy being explored for the treatment of
metastatic diseases such as TNBC is the use of oncolytic
viruses (OV). Several candidates are currently undergo-
ing clinical trials and are considered promising ap-
proaches for the treatment of various cancers including
TNBC [5]. At the forefront of this field is T-Vec, a her-
pes virus that was successfully tested in a phase III study
in melanoma and was approved in 2015 by the Food and
Drug Administration for clinical use. OVs specifically
replicate in and destroy tumor cells by several mecha-
nisms including direct oncolysis [6]. The rhabdovirus
family members, vesicular stomatitis virus (VSV) and
maraba, were first identified as oncolytic agents by
our group [7, 8]. The tumor specificity of these vi-
ruses is conferred by the capacity of normal cells, but
not tumor cells, to respond to antiviral interferons
(IFN) [7, 8]. Variants with a greater therapeutic index,
VSVΔ51 and Maraba MG1, were subsequently developed
for clinical use [8, 9]. Importantly, enrolling recently
began for a clinical trial using MG1 both as a stand-
alone therapy and in a vaccination strategy in patients
with late-stage disseminated disease (NCT02285816).
A means to further improve the efficacy of the virus is
to augment its replication in the tumor. In a previous
study, we identified drugs, so-called virus sensitizers
(VSe), that enhanced VSV replication in a tumor-specific
manner [10]. The compound identified as VSe12 in that
study is PAC and it demonstrated the ability to substan-
tially increase viral replication in vitro. Another VSe,
colchicine, affects microtubule dynamics and was also the
subject of a recent detailed study [11]. As opposed to
PAC, which stabilizes microtubules, colchicine has a de-
stabilizing effect, which also results in the blockade of cell
division [12]. Colchicine-mediated enhancement of VSV
was attributed in part to a defect in IFN secretion by
infected cells, thus preventing the cytokine-conferred
antiviral protection [11].
The combination of PAC with OV treatment has been
tested for vaccinia virus and herpes virus for other indi-
cations [13, 14]. This study focuses on the efficacy of
MG1 for breast cancer treatment and investigates the
co-treatment with PAC. Here, using three different mur-
ine breast cancer models, we demonstrate that MG1 can
be enhanced by PAC both in vitro and in vivo and that
the co-treatment improves efficacy better than either
treatment on its own without impairing the safety profile
of the virus.
Methods
Cell lines and culture
Vero kidney epithelial, 4 T1, EMT6 and EO771 murine
mammary carcinoma and Hs578T, BT-549 and MDA-
MB-231 human mammary carcinoma cell lines (American
Type Culture Collection (Manassas, VA, USA)) were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Corning cellgro, Manassas, VA, USA) supplemented
with 10 % fetal bovine serum (FBS) (Sigma life science,
St-Louis, MO, USA) and maintained at 37 °C with 5 % CO2.
Virus amplification and purification
MG1-green fluorescent protein (GFP) was purified as
previously described [8]. Briefly, Vero cells were infected
for 24 h at a multiplicity of infection (MOI) of 0.01. Su-
pernatants were then filtered using a 0.2-um bottle top
filter (Millipore, MA, USA) prior to 1.5-h centrifugation
at 30100 g. The pellet was resuspended in Dulbecco’s
phosphate-buffered saline (DPBS) (Corning cellgro, Ma-
nassas, VA, USA) and aliquots were stored at −80 °C.
PAC treatment
PAC was purchased from Accord healthcare Inc. (Durham,
NC). The cells were pre-treated at a concentration of 2 uM
in culture media for 4 h prior to infection, unless specified
otherwise. For in vivo experiments, animals were treated
intraperitoneally (IP) with 2 mg/kg or 10 mg/kg of PAC as
specified (see figure legends).
Virus titration
Titers were obtained by plaque assay. Briefly, serial
dilutions of the samples were transferred to monolayers of
Vero cells. Following an incubation of 1 h, cells were
overlaid with 0.5 % agarose/DMEM supplemented
with 10 % FBS. Plaques were counted 24 h later. For
in vivo experiments, tumors and organs were collected
48 h post treatment, homogenized in PBS using a tissue
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homogenizer, then serially diluted and virus quantified as
described above.
In vitro IFNβ treatment and quantification
Monolayers of tumor cells were treated with 250 U/mL
of murine IFNβ (PBL interferon source, Piscataway, NJ,
USA) 4 h prior to virus infection. The production of
IFNβ by tumor cells was quantified using the ELISA
mouse IFNβ kit (R&D systems, Minneapolis, MN, USA)
following the manufacturer’s protocol. The samples were
generated by pre-treating the cells with PAC as described
above and infecting them for 24 h at an MOI of 0.1.
Coomassie Blue staining/viability assay
At 72 h post infection, cells were fixed for 30 minutes
using fixative solution (3:1 methanol-acetic acid). The
fixative was then replaced by the Coomassie Blue stain-
ing solution (3:1 methanol-acetic acid, 0.1 % Commassie
Blue dye) for 30 minutes. The plates were washed and
dried overnight prior to scanning. For quantification,
the Coomassie Blue staining was solubilized using 10 %
SDS, and serial dilutions were performed and transferred
to a 96-well plate for reading using a Fluoroscan plate
reader at 450 nm.
Microscopy
For nuclear staining, cells were cultured and treated on
coverslips for 72 h. Cells were then washed with cold
PBS and fixed using ice-cold methanol-acetone (1:1).
Nuclei were stained using 4',6-diamidino-2-phenylindole
(DAPI) included in the Prolong gold anti-fade (Molecular
Probes) used to mount the coverslips onto slides. Live im-
ages of MG1-GFP infected cells were acquired using an
EVOS Fl cell imaging system (ThermoFisher Scientific)
microscope 24 h post infection.
Flow cytometry
For quantification of virus infection, cells were processed
as previously described [15]. Briefly, cells were harvested
and fixed using IC fixation buffer (eBioscience) 24 h
after PAC treatment and infection with MG1-GFP at an
MOI of 0.01. Cells were then washed twice and resus-
pended in FACS buffer (3 % FBS, PBS) for analysis
using a Cyan ADP 9 flow cytometer (Beckman Coulter,
Mississauga, ON, Canada).
In vivo experiments and tumor models
Balb/c mice were used (Charles River Laboratories) for
the 4 T1 and EMT6 murine tumor models. For orthotopic
implantation of the tumors, 2 × 105 cells were injected
into the second left mammary fat pad. For the EO771
tumor model, 1 × 106 cells were implanted into the second
left mammary fat pad of C57/Bl6 mice. For treatments,
the virus and drug preparations were diluted to the
appropriate concentration in a total volume of 100 uL of
PBS and injected IP or intratumorally (IT) using insulin
syringes (The Stevens Co, Montreal, QC, Canada). All
experiments were performed in accordance with the
University of Ottawa animal care and veterinary services
guidelines.
Histological analysis
Tumors were collected 48 h after treatment and fixed in
10 % buffered formalin phosphate (Fisher Scientific,
Waltham, MA, USA) for 48 h. Paraffin-embedded
sections were stained using hematoxylin and eosin or
the specified antibodies. For antibody staining, the
sections were rehydrated through graded alcohol and
heat-mediated antigen retrieval was performed in citrate
buffer (sodium citrate 10 mM, pH 6). Tissue sections were
stained as described previously [16] using a rabbit anti-
VSV (made in house) and rabbit anti-caspase-3 (Cell
signalling technology) antibodies.
TNBC ex-vivo samples
Patient-derived TNBC xenografts were grown into NOD/
SCID mice as described previously [17, 18]. When the
tumors reached 1500 mm3 in size they were collected and
cores were generated as described previously [19]. The
cores were treated ex-vivo with MG1 (103 plaque-forming
units (pfu)) and PAC and culture supernatant was
collected 48 h later to titer the virus output.
Tumor measurements and survival experiments
The length and width of the tumors were measured
using digital calipers (Fowler). The formula (length ×
width2)/2 was used to calculate tumor volumes. The
mice were sacrificed when they displayed respiratory dis-
tress, significant weight loss, ulceration, or discomfort,
or when the tumor volume reached 1500 mm3 in size.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 6.0 software (see figure legends). Error bars repre-
sent standard error of the mean.
Results
PAC treatment enhances MG1 replication and killing in
different breast cancer cell lines
In order to determine which concentration of drug and
MOI of virus to use in our experiment, we first assessed
the sensitivity of our different murine breast cancer cell
lines to either treatment. Using a GFP-expressing version
of MG1, we infected monolayers of cells at various MOIs
and assessed transgene expression as a readout of infectiv-
ity. We also evaluated virus-mediated killing of the cells
by looking at visible cytotoxicity. Our results demonstrate
various sensitivities to the virus with the E0771 cells being
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completely infected at an MOI of 0.01 and all dead at an
MOI of 10, and the EMT6 cells being the most resistant
with only a few cells expressing GFP at an MOI of 10
(Fig. 1). The 4 T1 cells displayed an intermediate pheno-
type. We then investigated the sensitivity of the cell lines
to PAC-induced killing. To do so, we incubated
monolayers of cells with increasing concentrations of the
drug for 48 h and performed a Coomassie Blue viability
assay where decreased staining intensity reveals cyto-
toxicity. Similar to what we observed with the virus, the
EO771 cells were the most sensitive to PAC and the
EMT6 the most resistant cell line (Additional file 1:
Fig. 1 Murine breast cancer cell lines display different sensitivities to MG1. Microscopy images of EMT6, 4 T1 and EO771 tumor cells infected with
various multiplicities of infection of MG1-green fluorescent protein for 24 h
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Figure S1a). The concentrations required to kill the vari-
ous tumor cells ranged from 4 uM to 12 uM. To investi-
gate the responsiveness of the cell lines to PAC-mediated
inhibition of cellular division, we stained the nucleus of
treated cells in order to detect enlarged, polynuclear
cells. Interestingly, all three tumor cell lines were re-
sponsive to low, sub-lethal concentrations of PAC
(0.5 uM) (Additional file 1: Figure S1b).
To evaluate the effect of PAC on viral replication, we
assessed the presence of GFP-positive cells following co-
treatment with the drug in our murine breast cancer cell
lines. We pre-treated the cells for 4 h with 2 uM of
PAC, a concentration at which all cell lines displayed
polynucleation, but none of them exhibited drug-
mediated killing (Additional file 1: Figure S1). Our re-
sults indicate the presence of more MG1-infected EMT6
and 4 T1 cells for the co-treatment conditions (Fig. 2a,
left panels). This enhancement was confirmed by quanti-
fication of the virus in the supernatants where 10-fold to
100-fold more virus was detected in the presence of the
drug (Fig. 2a, right panels). For the E0771 cell line, no
difference was observed in virus recovery and GFP ex-
pression, demonstrating that the drug did not enhance,
but did not impair virus production either. We obtained
similar results using three different human TNBC cell
lines, whereby virus enhancement was observed in two
cell lines (MDA-MB-231 and BT-549) but not in the
third (Hs578T) (Fig. 2b). We used flow cytometry as a
means to quantify the percentage of GFP-expressing
cells and the mean fluorescence value (MFV) of infected
cells in the presence or absence of the drug. Our results
demonstrate that there were more GFP-positive cells
Fig. 2 Paclitaxel (PAC) enhances MG1 in various human and mouse breast tumor cell lines. a Microscopy images of EMT6, 4 T1 and EO771 tumor
cells infected with MG1-green fluorescent protein (GFP) after a 4-h pre-treatment with 2 uM PAC. Graphs right represent virus titers obtained 24 h
post infection. ND no drug, pfu plaque-forming units. b Microscopy images of MDA-MB-231, BT-549 and Hs578T human tumor cells infected with
MG1-GFP after a 4-h pre-treatment with 2 uM PAC. Flow cytometry histograms show the GFP expression of infected EMT6 (c) or (d) 4 T1 cells
24 h post infection with or without PAC pre-treatment. The right graphs show percentage of GFP+ cells and the mean fluorescence values (MFV).
Samples were analyzed in triplicates. Statistical significance was tested using the unpaired two-tailed t test with Welch’s correction; *p < 0.05,
**p < 0.01 ***p < 0.001. Ctrl control
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when we pre-treated the 4 T1 and EMT6 cells with PAC,
with percentages and average fluorescence twofold to
threefold higher in the presence of the drug (Fig. 2c and d).
In a recent study we demonstrated that the viral
sensitization mediated by colchicine, another drug affect-
ing microtubules and preventing cell division was medi-
ated by a blockade in the secretion of antiviral IFNs [11].
As many tumor cell lines are refractory to antiviral IFNs
and would thus be refractory to enhancement involving
this mechanism of action [7], we first assessed the sensitiv-
ity of our cell lines to the cytokine. Additional file 2:
Figure S2a shows that pre-treating the cells with IFNβ effi-
ciently protected all three cell lines against the virus. Con-
sistent with this, less killing of the cells was observed with
IFNβ pre-treatment (Additional file 3: Figure S3). To
measure the IFNβ production in response to virus infec-
tion, we performed an ELISA on culture supernatants of
infected cells. For all three cell lines, the cytokine was de-
tected following infection. Interestingly, and consistent
with our virus enhancement data (Fig. 2), our results show
that in both EMT6 and 4 T1 cells, the production of IFNβ
was impaired in the presence of PAC, while the levels pro-
duced by the E0771 cells were unaffected by the drug
(Additional file 2: Figure S2b).
As the aim of both MG1 and PAC treatments is ultim-
ately to kill tumor cells, we assessed cell death following
co-treatment. We used a concentration of the drug
where no cytotoxicity was observed following a 48-h in-
cubation. For all three murine cell lines, we observed
more cytotoxicity in the presence of both treatments
with almost all the cells being dead, suggesting synergis-
tic rather than cumulative killing (Fig. 3a). This decrease
in viability was confirmed by quantification of the stain-
ing (Additional file 4: Figure S4). This synergistic killing
was also confirmed using the MDA-MB-231, BT-549
and Hs578T human cell lines (Fig. 3b).
The virus is enhanced by PAC treatment in vivo
We then sought to confirm our in vitro findings in
tumor-bearing animals. We implanted tumors orthotopi-
cally in order to recapitulate the natural microenviron-
ment as much as possible. The virus was administered
IT and quantified 48 h later by plaque assay. Our results
demonstrate that threefold to fourfold more virus was
detected in the EMT6 and 4 T1 tumors of the animals
that also received PAC treatment compared to those that
were treated with MG1 alone (Fig. 4a and b). For the
E0771 tumor-bearing animals, we did not observe any
difference in the amount of virus we recovered, consist-
ent with the in vitro findings using this cell line (Figs. 2a
and 4c). In order to assess if the increased viral replica-
tion would also result in increased replication in normal
organs and impair the safety of the treatment, we per-
formed a biodistribution experiment of MG1 48 h post
injection in EMT6-tumor-bearing animals using the two
drug concentrations used in this study. Our data demon-
strate that, while both drug concentrations were able to
increase viral replication in the tumors, no differences
were observed in normal organs following co-treatment
(Fig 4d).
To confirm the positive effect of PAC-treatment on
MG1 infection of human tumors, we used a breast can-
cer patient xenograft model that was previously de-
scribed to recapitulate the human disease [17, 18]. We
infected tumor cores ex vivo in the presence or absence
of PAC. Our results demonstrate that PAC efficiently
enhanced viral replication in a TNBC patient-derived
xenograft (Fig. 4e).
PAC-MG1 combination therapy demonstrates greater
tumor killing in vivo
Previous work by Lin et al. demonstrates that while both
PAC and an oncolytic herpes simplex virus induce apop-
tosis, the combination of both was more effective in hu-
man anaplastic thyroid cancer cell lines [14]. To investigate
if this was also the case using MG1 in our tumor models,
we performed immunohistochemical analysis against the
cleaved pro-apoptotic molecule caspase-3 on EMT6 tu-
mors from mice that received the various treatments. First,
the hematoxylin and eosin staining clearly demonstrated
the presence of widespread necrotic regions for the MG1
as well as the MG1 and PAC co-treated tumors (Fig. 5,
left panels). This was confirmed by caspase-3 staining,
which was extensive in these tumors. (Fig. 5, right panels).
Fig. 3 Paclitaxel (PAC) and MG1 synergistically kill breast cancer cell lines. Coomassie Blue staining of EMT6, 4 T1 and EO771 (a) and MDA-MB-231,
BT-549 and Hs578T cells (b) infected or not with MG1-green fluorescent protein and co-treated with 2 uM PAC for 48 h. ND no drug
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These regions were larger and more abundant in the co-
treated animals compared to those that received the MG1
treatment only. Also, consistent with the virus quantifica-
tion shown in Fig. 4a, staining of the tumor sections with
a virus-specific antibody demonstrated increased virus
spread in the presence of PAC (Fig. 5, middle panels).
The treatment with MG1 and PAC demonstrates greater
efficiency in murine tumor models
Given the improved killing observed with PAC in all
three cell lines in vitro, the increased virus recovery
from tumors and the greater caspase-3-positive tumor
regions observed in the presence of the co-treatment, we
sought to determine if these phenomena would translate
into slower tumor growth and an improvement in
the survival of tumor-bearing animals. The mice were
treated with MG1, PAC or both and tumors were
measured over time. As expected, we observed that the
growth was slower following treatment with the combin-
ation of the virus and the drug in all three tumor models
(Fig. 6a, b and c, upper panels). Also, as observed in vitro,
the E0771 model was the most sensitive to both treat-
ments. Importantly, the enhanced control of tumor
growth translated into a significant prolongation of sur-
vival in all three models and some animals were even
cured for the 4 T1 and E0771 tumor models (Fig. 6a, b
and c, bottom panels).
Discussion
In this study, we demonstrated the compatibility of PAC,
a standard-of-care chemotherapeutic agent for breast
cancer, and MG1, an OV that is considered a promising
and novel strategy for treating disseminated diseases like
breast cancer. Our results not only show that treatments
do not interfere with one another, but they can also per-
form even better when co-administered. Using three dif-
ferent syngeneic murine breast cancer models, we show
a prolongation of survival for animals that received both
treatments compared to either treatment alone (Fig. 6).
These findings have potential implications for the future
treatment of patients. Our data support clinical testing
of the combination. Even if the patient’s cancer has be-
come resistant to the drug, it might still effectively en-
hance MG1 and at the very least, should not impair the
viral treatment. Second, because the beneficial effects we
observed were achieved using sub-lethal concentrations
of PAC and knowing the various side effects of the drug
in patients with cancer, it is tempting to suggest that
using a lower concentration of PAC in combination with
the virus would be a suitable strategy.
Interestingly, we found that two out of the three mur-
ine tumor cell lines and the human tumor cell lines that
we tested were sensitized to viral infection by PAC
(Fig. 2). Indeed, while EMT6 and 4 T1 cells produced
more virus when pre-treated with the drug, the E0771
Fig. 4 Paclitaxel (PAC) enhances MG1 replication in tumors. EMT6 (a), 4 T1 (b) or EO771 (c) tumor-bearing mice were treated intratumorally with
1 × 108 plaque-forming units (pfu) of MG1-green fluorescent protein (GFP) and intraperitoneally with PAC (10 mg/kg for the EMT6 model and
2 mg/kg for the 4 T1 and EO771 models). Tumors were harvested 48 h later and the viral quantification was obtained by plaque assay. Three or
more tumors per condition were analysed. d EMT6 tumor-bearing mice were treated as in a and various organs were collected 48 h post treatment.
The virus was quantified by plaque assay. e Tumor cores from human triple-negative breast cancer xenografts were infected ex-vivo with MG1-GFP
with or without PAC co-treatment. The viral outputs were quantified by plaque assay. Statistical significance was calculated using the unpaired
two-tailed t test with Welch’s correction; *p < 0.05, **p < 0.01, ***p < 0.001. ND no drug
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cell line was not affected. Our model is that PAC pre-
treatment would block the secretion of antiviral factors
like IFNβ by infected cells (Additional file 2: Figure S2B),
thereby increasing virus infection. In line with this idea,
both EMT6 and 4 T1 cells in which we see sensitization
to the virus, but not the E0771 cells, which are refractory
to this effect, demonstrated impaired production of the
antiviral cytokine (Additional file 2: Figure S2B). Import-
antly, our results also show that while ex-vivo infection
and treatment of patient breast cancer xenografts can
inform us on the potential enhancement of the virus by
the drug in specific patient samples (Fig. 4e), the lack
of enhancement would not necessarily imply that both
treatments would not be compatible. Indeed, increased
production of virus is desirable, but the killing of the
target tumor cells is what ultimately matters. Our data
show that although the E0771 cell line does not demon-
strate sensitization to the virus in the presence of PAC,
complete killing of the cells was still observed at con-
centrations of PAC and MG1 that did not affect cell
viability alone. Notably, the E0771 tumor model was
the one in which we observed the highest percentage of
cures with the treatment combination (Fig. 6c). This is
most likely due to the greater sensitivity of the E0771
tumors to both single treatments alone compared to
the two other tumor models (Fig. 6). Remarkably, while
the EMT6 and 4 T1 tumors are slightly smaller com-
pared to the control animals when treated with either
the virus or the drug, the combination of both treat-
ments was the only condition that was significantly dif-
ferent in terms of the ability to control tumor growth
and prolong survival.
Fig. 5 The co-treatment with paclitaxel (PAC) and MG1 increases tumor apoptosis. EMT6 tumor-bearing animals were treated intratumorally with
MG1-green fluorescent protein (108 plaque-forming units) and intraperitoneally with 10 mg/kg with PAC, and tumor samples were harvested 48 h
post treatment. Sections were stained for the presence of virus and apoptotic cells (caspase-3)
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An interesting idea to explain the improved killing ob-
served in vitro in the E0771 cell line would be that
virus-induced factors may promote PAC killing. Indeed,
it has been reported by Thorne and colleagues that
oncolytic vaccinia virus induces the secretion of factors,
including type I IFNs, which sensitize tumor cells to
taxol [13]. Also, a similar mechanism was observed for
the colchicine and VSV co-treatment [11]. This scenario
would provide a mechanism by which even tumors
that are refractory to the PAC-mediated sensitization
to MG1 could still benefit from the combination. Of
note, infection with vaccinia virus produces various
anti-inflammatory factors [20], including B18R which
inhibits the activity of IFNs and could potentially
minimize this effect, while MG1 and VSV do not encode
these inhibitors, suggesting that the virus-mediated
sensitization of tumor cells to PAC-mediated killing could
be even greater [7, 8].
Another interesting application of our combination
strategy would be to potentiate the production of virally-
encoded transgenes. The engineering of oncolytic viruses
has been shown to be a successful strategy for tumor-
targeted gene delivery and improvement of treatment ef-
ficacy. Indeed, rhabdoviruses encoding antiviral suppres-
sors to increase viral replication [21], suicide genes to
improve killing [22] or immune-stimulating cytokines to
induce a greater anti-tumor immune response [23] have
all been shown to control tumor growth more efficiently
compared to the parental virus. Given that, along with the
increased virus production, we also observed more GFP-
positive cells and higher MFV (Fig 2b and c) and thus,
greater transgene production, the co-treatment could po-
tentially be even more beneficial using viruses that encode
transgenes that mediate greater control of the tumors.
Conclusions
With the urgent need for novel strategies for breast cancer
treatment, especially in patients with TNBC, which are re-
fractory to the limited available treatment options, our
work provides a rational alternative to improve outcomes.
Our data demonstrate that the combination of PAC and
MG1 is effective at controlling tumor progression. Because
PAC is a standard of care for breast cancer treatment and
MG1 is undergoing clinical testing, we believe the findings
included in this study are of great importance and that the
translation of this work to the clinic could be rapid.
Additional files
Additional file 1: Figure S1. Murine breast cancer cell lines display
different sensitivities to PAC. A EMT6, 4 T1 and EO771 cells were treated
with increasing concentrations of PAC. Coomassie Blue staining was used
Fig. 6 The combination of Paclitaxel (PAC) and MG1 improves efficacy in various murine breast cancer models. Volumes of EMT6 (a), 4 T1 (b) or
EO771 (c) fat-pad tumors in mice treated or not (NT) with MG1-green fluorescent protein (1 × 108 pfu) in combination or not with PAC (10 mg/kg
for EMT6 and 2 mg/kg for 4 T1 and EO771). Mice were sacrificed when they reached the endpoint. NS p > 0.05, *p < 0.1, **p < 0.01, ***p < 0.001
(unpaired multiple two-tailed t test). Kaplan-Meier survival curves were generated from the same experiments (bottom panels). For survival experiments,
NS p > 0.1, *p < 0.1, **p < 0.01, ***p < 0.001 (Mantel-Cox test)
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to assess the toxic dose of the drug in the different cell lines after 72 h.
B Fluorescent microscopy pictures of DAPI-stained cells with or without
treatment with 0.5uM PAC for 72 h. (TIF 14849 kb)
Additional file 2: Figure S2. PAC blocks IFNβ production by infected
tumor cells. A Microscopy pictures of EMT6, 4 T1 and EO771 tumor cells
pre-treated or not for 4 h with recombinant IFNβ. B The IFNβ released
from MG1-infected cells in the presence or absence of PAC was quantified
by ELISA. Samples were analysed in triplicates and statistical significance
was calculated using the unpaired two-tailed t test with Welch’s correction;
*p < 0.05, **p < 0.01, ***p < 0.001. (TIF 6796 kb)
Additional file 3: Figure S3. IFNβ pre-treatment protects EMT6, 4 T1
and EO771 cells from virus-mediated killing. Coomassie Blue staining of
the various breast cancer cell lines 48 h post infection with MG1-GFP with
or without pre-treatment with recombinant murine IFNβ. (TIF 2149 kb)
Additional file 4: Figure S4. PAC and MG1 synergistically kill breast
cancer cell lines. Quantification of the signal obtained for triplicates or
quadruplicates Coomassie Blue staining of EMT6, 4 T1 or EO771 cells
infected or not with MG1-GFP and co-treated with 2 uM PAC for 48 h
from Fig. 3. Statistical significance was calculated using the unpaired
two-tailed t test with Welch’s correction; *p < 0.05, **p < 0.01, ***p < 0.001.
(TIF 2942 kb)
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